

~~5~~ 33. (Currently Amended) The method of claim ~~20~~, wherein decitabine is administered to the patient intravenously per day at a dose ranging from 5 to 20 mg/m<sup>2</sup>.

~~6~~ 34. (Previously Amended) A method for treating a cancer patient, comprising: administering intravenously to the cancer patient decitabine at a dose ranging from 1 mg/m<sup>2</sup> per day to 20 mg/m<sup>2</sup> per day, for at least 3 days per treatment cycle, in combination with a therapeutically effective amount of an anti-neoplastic agent whose activity as an anti-neoplastic agent in vivo is adversely affected by aberrant DNA methylation, wherein the cancer is selected from the group consisting of ovarian, breast, prostate, gastric, lung, pancreas and colon cancer and is refractory to the treatment of the anti-neoplastic agent alone.

~~7~~ 35. (Currently Amended) The method of claim ~~20~~, wherein the DNA methylation inhibitor decitabine is administered prior to the administration of the anti-neoplastic agent.

36.-41. (Withdrawn)

42-43. (Cancelled)

~~8~~ 44. (Previously Added) A method of claim ~~20~~, wherein the anti-neoplastic agent is cisplatin or carboplatin.

~~9~~ 45. (Previously Added) A method of claim ~~20~~, wherein decitabine is administered to the patient intravenously.

~~10~~ 46. (Previously Added) A method of claim ~~20~~, wherein decitabine is administered to the patient intravenously, at a dose ranging from 5 mg/m<sup>2</sup> to 20 mg/m<sup>2</sup>, per day.

~~11~~ 47. (Previously Added) A method of claim ~~20~~, wherein decitabine is administered prior to the administration of the anti-neoplastic agent.

48. (Cancelled)

~~12~~ 49. (Previously Added) A method of claim ~~20~~, wherein the anti-neoplastic agent is cisplatin or carboplatin.

D  
M

**B**  
~~50.~~ (Previously Added) A method of claim 34, wherein decitabine is administered prior to the administration of the anti-neoplastic agent.

**b**